Cyclophosphamide News and Research

RSS
Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

Rituxan receives FDA approval for treating two rare diseases

Rituxan receives FDA approval for treating two rare diseases

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Leukemia & Lymphoma publishes CTI's CPOP phase I/II trial results against NHL

Leukemia & Lymphoma publishes CTI's CPOP phase I/II trial results against NHL

TESE offers fertility to male cancer survivors

TESE offers fertility to male cancer survivors

TESE surgical technique can help men with childhood cancer experience parenthood

TESE surgical technique can help men with childhood cancer experience parenthood

New PTLD Guideline highlighted at NCCN Annual Conference

New PTLD Guideline highlighted at NCCN Annual Conference

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

Solasia, ZIOPHARM enter license and collaboration agreement for darinaparsin product

Solasia, ZIOPHARM enter license and collaboration agreement for darinaparsin product

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

Allos reaches SPA agreement with FDA for FOLOTYN Phase 3 trial in PTCL

Less-toxic combination of immune-based drug and chemotherapy drug produce long-term remissions in CLL

Less-toxic combination of immune-based drug and chemotherapy drug produce long-term remissions in CLL

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma

ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics